Related Experiment Video
Updated: Jun 15, 2026

Galleria mellonella as an Antimicrobial Screening Model
Published on: October 11, 2024
Once-daily gentamicin dosing in pediatric patients without cystic fibrosis
Erin J McDade1, Jeffrey L Wagner, Brady S Moffett
1Department of Pharmacy, Texas Children's Hospital, Houston, Texas 77030, USA.
Insights
This study determined age-based, once-daily gentamicin dosing for pediatric patients. Age significantly impacts gentamicin dosage, with specific mg/kg recommendations provided for different pediatric age groups.
Area of Science:
- Pediatric Pharmacology
- Antibiotic Dosing Optimization
- Pharmacokinetic Analysis
Background:
- Gentamicin dosing requires careful consideration in pediatric populations.
- Establishing optimal once-daily dosing regimens is crucial for efficacy and safety.
Purpose of the Study:
- To determine appropriate once-daily gentamicin doses and intervals for non-critical care pediatric patients over 3 months old.
- To identify patient factors influencing gentamicin pharmacokinetics.
Main Methods:
- Retrospective analysis of pharmacokinetic data from 114 pediatric patients.
- Calculation of patient-specific pharmacokinetic parameters at steady state.
- Extrapolation of once-daily gentamicin doses to achieve target peak and trough concentrations.
Main Results:
- Age was the sole significant demographic factor affecting gentamicin peak concentrations.
- Calculated age-specific once-daily gentamicin doses: 9.5 mg/kg (3 months to <2 years), 8.5 mg/kg (2 to <8 years), and 7 mg/kg (8-18 years).
- Mean elimination rate constant: 0.32 hr⁻¹, half-life: 2.28 hours, volume of distribution: 0.24 L/kg.
Conclusions:
- Age is the primary determinant for once-daily gentamicin dosing in pediatric patients.
- Prospective studies are needed to validate the safety and efficacy of these age-based dosing recommendations.
Study Objective:
To estimate an appropriate once-daily gentamicin dose and dosing interval for non-critical care pediatric patients older than 3 months of age without cystic fibrosis.
Design:
Pharmacokinetic analysis of data from a retrospective medical record review.
Setting:
Large academic children's hospital.
Patients:
One hundred fourteen non-critical care pediatric patients older than 3 months of age without cystic fibrosis who received multiple-daily dosing regimens of gentamicin between September 2007 and April 2008.
Measurements And Main Results:
Patient-specific pharmacokinetic parameters were calculated using drug concentrations obtained at steady state. Once-daily doses were extrapolated for each patient to achieve goal peak and trough concentrations. Using the average of these doses and the patient-specific pharmacokinetic parameters, theoretical once-daily peak and trough concentrations were calculated for each patient. Patient characteristics were analyzed to determine differences between patients who did and those who did not achieve adequate peak concentrations. Mean +/- SD pharmacokinetic parameters were as follows: elimination rate constant 0.32 +/- 0.06 hour(-1), half-life 2.28 +/- 0.54 hours, and volume of distribution 0.24 +/- 0.08 L/kg. The only patient demographic characteristic found to have a significant effect on the extrapolated peak concentration was age. The following age-specific once-daily doses were calculated: 3 months to less than 2 years, 9.5 mg/kg; 2 years to less than 8 years, 8.5 mg/kg; and 8-18 years, 7 mg/kg.
Conclusion:
Age was the primary factor in determining the once-daily dose of gentamicin in our pediatric population. Further prospective research is necessary to determine the safety and efficacy of these age-based, once-daily doses for gentamicin.
Related Concept Videos
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Pharmacokinetics in Pediatric Patients: Drug Excretion
Estimation of k and VD of Aminoglycosides
Drug Dosing: Infants and Children
Dosage Regimen: Multiple Oral Dosage
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
